There was no significant difference in serum ALT and AST between the two groups, suggesting that VEGFB affected the lipid metabolism of NAFLD mice hepatocytes, and whether VEGFB had an impact on hepatocyte proliferation and apoptosis remains to be further studied. Here, VEGFB is linked to metabolic dysfunction-associated steatotic liver disease.